SCHOTT to Expand Borosilicate Glass Tubing Capacity with New Plant in China
Due to the increasingly stringent regulatory framework to support patient safety standards in China, the demand for high-quality drug packaging products is steadily increasing.
SCHOTT recently announced that it has signed an investment agreement to build a pharmaceutical tubing production site in Zhejiang Province, China. In light of the growing demand for high-quality Type 1 pharmaceutical tubing in China, SCHOTT will invest in a greenfield site for the production of FIOLAX® tubing.
“The new production site in Jinyun County, Zhejiang Province, is a clear commitment to developing the local market,” said Patrick Markschläger, Ph.D., executive vice president of SCHOTT AG Business Unit Tubing. “The site will feature the company’s most advanced production technology, which will strongly support the further development of the domestic pharmaceutical industry.”
Due to the increasingly stringent regulatory framework to support patient safety standards in China, the demand for high-quality drug packaging products is steadily increasing. According to SCHOTT, its FIOLAX glass tubing is widely used for high-quality pharmaceutical containers such as vials, ampoules, cartridges, and syringes.
For more information, visit www.schott.com.